The structural distinction between Melanotan I and Melanotan II, why related drug names do not identify a research vial, and how to read material-specific evidence.
Melanotan I and Melanotan II are distinct analogues associated with alpha-melanocyte-stimulating hormone terminology. The Roman numeral is part of the identity. It must not be dropped when comparing a catalogue listing, a study or an analytical report.
Melanotan I is associated with the name afamelanotide and a 13-residue peptide structure. Melanotan II is a cyclic seven-residue analogue. The PubChem afamelanotide record and Dorr and colleagues' 1996 MT-II paper document these distinct structures. A relationship to the same parent hormone does not make the compounds interchangeable.
Sequence length is only one identifier. Terminal modifications, stereochemistry and cyclisation can also distinguish peptide structures. A report should name the specific target rather than use a family label that could describe several materials. A comparison based only on vial quantity leaves that identity question unanswered.
Our Melanotan I versus II comparison focuses on these distinctions. The Melanotan II identity guide covers the compound listed in the current catalogue. Neither article turns a research-material description into a recommendation for human use.
Afamelanotide appears in authorised pharmaceutical documentation, including the SCENESSE prescribing information. That document describes a particular finished medicine. It does not establish the regulatory status, formulation, manufacture or suitability of a separately sold laboratory vial, and it does not apply to Melanotan II simply because the names share a root.
When interpreting a source, identify both the molecule and the actual preparation studied. Separate a chemical identity record, a laboratory experiment, a small clinical study and a medicine's product information. They answer different questions.
The 1996 MT-II paper is a small pilot study, not an analysis of PCUK's material or a general assurance about all products sold under that name. Published findings stay attached to the studied preparation, participants or model and methods. This reference does not reproduce administration schedules or infer an outcome for a research vial.
For the supplied Melanotan II 10mg listing, check its full name, labelled quantity, form, batch and linked documentation. A certificate describes the tested sample within the limits of its methods; it cannot establish a therapeutic or cosmetic result. The COA guide explains those limits, and the report library shows the reports currently published.
Materials supplied by this site are solely for non-clinical in-vitro laboratory research, not for use in or on humans or animals. This reference provides no dosing, administration, treatment or in-vivo protocol. Laboratory work requires an appropriate institutional SOP and risk assessment.
What Melanotan II is, how it relates to alpha-MSH, which melanocortin receptors it binds, and why it has never been a licensed medicine anywhere.
Research DocumentationOne is linear, selective and a licensed medicine under another name. The other is cyclic, non-selective and never licensed. The structural and regulatory differences explained.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.